New findings showed that enfortumab vedotin plus pembrolizumab improved survival when compared with platinum-based chemotherapy among #UrothelialCancer patients without compromising quality of life and functioning. https://t.co/ENWJfhtRAu #CancerResearch https://t.co/ISbfs80d9M